Free tool
FAERS Monitor: Ameluz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208081 or its brand name (Ameluz, Aminolevulinic Acid Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
292
Serious
112
38% of reports
Hospitalization
29
Death reported
7
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use74
- application site pain59
- application site erythema50
- hypotension30
- drug ineffective17
- application site swelling16
- product odour abnormal15
- pain12
- product colour issue11
- application site pustules10
- application site vesicles10
- erythema10
- hypersensitivity10
- nausea10
- vomiting9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 25 |
| 2018 | 26 |
| 2019 | 24 |
| 2020 | 18 |
| 2021 | 30 |
| 2022 | 30 |
| 2023 | 42 |
| 2024 | 35 |
| 2025 | 32 |
| 2026 | 23 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,867 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| application site pustulesSignal | 10 | 2031.1 | 1094.9 | 17,810 |
| application site swellingSignal | 16 | 232.0 | 143.9 | 3,442 |
| application site painSignal | 59 | 193.4 | 154.0 | 11,086 |
| product colour issueSignal | 11 | 154.7 | 86.6 | 1,527 |
| application site erythemaSignal | 50 | 137.7 | 106.9 | 6,644 |
| application site vesiclesSignal | 10 | 111.2 | 60.5 | 984 |
| product odour abnormalSignal | 15 | 103.3 | 63.1 | 1,418 |
| hypotensionSignal | 30 | 10.8 | 7.7 | 259 |
| off label useSignal | 74 | 6.1 | 5.0 | 323 |
| hypersensitivitySignal | 10 | 3.9 | 2.1 | 19 |
| erythemaSignal | 10 | 3.5 | 1.9 | 16 |
| pain | 12 | 1.4 | 0.8 | 1 |
| vomiting | 9 | 1.4 | 0.7 | 1 |
| drug ineffective | 17 | 0.9 | 0.6 | 0 |
| nausea | 10 | 0.9 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.